Your Health, We Care
Coadministration of Larotrectinib with a strong or moderate CYP3A4 inhibitor may increase larotrectinib plasma concentrations, which may result in a higher incidence of adverse reactions. Avoid coadministration of Larotrectinib with strong CYP3A4 inhibitors, including grapefruit or grapefruit juice. If coadministration of strong CYP3A4 inhibitors cannot be avoided, modify Larotrectinib dose as recommended. In patients coadministered a moderate CYP3A4 inhibitor with Larotrectinib, monitor for adverse reactions more frequently and reduce the Larotrectinib dosage based on the severity of emergent adverse reactions.
Coadministration of Larotrectinib with a strong or moderate CYP3A4 inducer may decrease larotrectinib plasma concentrations, which may decrease the efficacy of Larotrectinib. Avoid coadministration of Larotrectinib with strong CYP3A4 inducers, including St. John’s wort. If coadministration of strong CYP3A4 inducers cannot be avoided, modify Larotrectinib dose as recommended. For coadministration with moderate CYP3A4 inducers, modify Larotrectinib dose as recommended.
Coadministration of Larotrectinib with sensitive CYP3A4 substrates may increase their plasma concentrations, which may increase the incidence or severity of adverse reactions. Avoid coadministration of Larotrectinib with sensitive CYP3A4 substrates. If coadministration of these sensitive CYP3A4 substrates cannot be avoided, monitor patients for increased adverse reactions of these drugs.
from FDA，2022.11
